Lack of modifying effects of atrazine and/or tamoxifen on thyroid carcinogenesis in rats pretreated with N-bis(2-hydroxypropyl)nitrosamine (DHPN)

Food and Chemical Toxicology

Volumn 41, Issue 12, 2003, Pages 1811-1816

  Son, Hwa Young ^a,b   Nishikawa, Akiyoshi ^a   Okazaki, Kazushi ^a   Lee, Kyong Youl ^a,b   Imazawa, Takayoshi ^a   Hirose, Masao ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b Chungnam National University   (South Korea)

Author keywords

Atrazine; Endocrine disruptor; Tamoxifen; Thyroid carcinogenesis

Indexed keywords

ATRAZINE; BIS(2 HYDROXYPROPYL)NITROSAMINE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BRAIN; CANCER MODEL; CARCINOGENESIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFECT; EPIDIDYMIS; HISTOPATHOLOGY; HYPOPHYSIS; KIDNEY; LIVER WEIGHT; MALE; NONHUMAN; ORGAN; RAT; TESTIS; THYROID CANCER; THYROID GLAND; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALIA;

EID: 0141963264     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-6915(03)00234-5     Document Type: Article

References (34)

1. Anker G.B., Lonning P.E., Aakvaag A., Lien E.A. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scand. J. Clin. Lab. Invest. 58:1998;103-107.
2. Banu S.K., Govindarajulu P., Aruldhas M.M. Testosterone and estradiol differentially regulate TSH-induced thyrocyte proliferation in immature and adult rats. Steroids. 67:2002;573-579.
3. Beyssen M., Lagorce J., Cledat D., Jambut A., Buxeraud J. Antithyroid action of tamoxifen in the rat. in vivo and in vitro studies Pharmacology. 61:2000;22-30.
4. Calvert G.M., Sweeney M.H., Deddens J., Wall D.K. Evaluation of diabetes mellitus, serum glucose, and thyroid function among United States workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Occup. Environ. Med. 56:1999;270-276.
5. Cheek A.O., Kow K., Chen J., McLachlan J.A. Potential mechanisms of thyroid disruption in humans. interaction of organochlorine compounds with thyroid receptor, transthyretin, and thyroid-binding globulin Environ. Health Perspect. 107:1999;273-278.
6. Connor K., Howell J., Chen I., Liu H., Berhane K., Sciarretta C., Safe S., Zacharewski T. Failure of chloro-S-triazine-derived compounds to induce estrogen receptor-mediated responses in vivo and in vitro. Fundam. Appl. Toxicol. 30:1996;93-101.
7. Cooper R.L., Stoker T.E., Tyrey L., Goldman J.M., McElroy W.K. Atrazine disrupts the hypothalamic control of pituitary-ovarian function. Toxicol. Sci. 53:2000;297-307.
8. Danzo B.J. Environmental xenobiotics may disrupt normal endocrine function by interfering with the binding of physiological ligands to steroid receptors and binding proteins. Environ. Health Perspect. 105:1997;294-301.
9. Dipippo V.A., Powers C.A. Tamoxifen and ICI 182,780 interactions with thyroid hormone in the ovariectomized-thyroidectomized rat. J. Pharmacol. Exp. Ther. 281:1997;142-148.
10. D'Mello D., Mehta D., Pereira J., Rao C.V. A toxicity study of simultaneous administration of tamoxifen and diazepam to female Wistar rats. Exp. Toxicol. Pathol. 51:1999;549-553.
11. Ghinea E., Simionescu L., Oprescu M. Studies on the action of pesticides upon the endocrines using in vitro human thyroid cells culture and in vivo animal models. I. Herbicides - aminotriasole (amitrol) and atrazine. Endocrinologie. 17:1979;185-190.
12. Gordon D., Beastall G.H., McArdle C.S., Thomson J.A. The effect of tamoxifen therapy on thyroid function tests. Cancer. 58:1986;1422-1425.
13. Gross C., Yu M., Van Herle A.J., Giuliano A.E., Juillard G.J. Presence of a specific antiestrogen binding site on human follicular thyroid carcinoma cell line (UCLA RO 82 W-1). inhibition by an endogenous ligand present in human serum J. Clin. Endocrinol. Metab. 77:1993;1361-1366.
14. Hayes T., Haston K., Tsui M., Hoang A., Haeffele C., Vonk A. Herbicides. feminization of male frogs in the wild Nature. 419:2002;895-896.
15. Atrazine. IARC Sci. Publ. 73. 1999;IARC, Lyon.
16. Ickenstein L.M., Bandiera S.M. Persistent suppression of hepatic CYP2A1 expression and serum triiodothyronine levels by tamoxifen in intact female rats. dose-response analysis and comparison with 4-hydroxytamoxifen, fulvestrant (ICI 182,780), and 17beta-estradiol-3-benzoate J. Pharmacol. Exp. Ther. 302:2002;584-593.
17. Karami-Tehrani F., Salami S., Mokarram P. Competition of tamoxifen with thyroxine for TBG binding. ligand binding assay and computational data Clin. Biochem. 34:2001;603-606.
18. Kishino T., Watanabe M., Kimura M., Sugawara I. Anti-proliferative effect of toremifene and tamoxifen on estrogen receptor-lacking anaplastic thyroid carcinoma cell lines. Biol. Pharm. Bull. 20:1997;1257-1260.
19. Kniewald J., Jakominic M., Tomljenovic A., Simic B., Romac P., Vranesic D., Kniewald Z. Disorders of male rat reproductive tract under the influence of atrazine. J. Appl. Toxicol. 20:2000;61-68.
20. Kohn M.C., Sewall C.H., Lucier G.W., Poriter C.J. A mechanistic model of effects of dioxin on thyroid hormones in the rat. Toxicol. Appl. Pharmacol. 136:1996;29-48.
21. Kornilovskaya I.N., Gorelaya M.V., Usenko V.S., Gerbilsky L.V., Berezin V.A. Histological studies of atrazine toxicity on the thyroid gland in rats. Biomed. Environ. Sci. 9:1996;60-66.
22. Kostoglou-Athanassiou I., Ntalles K., Markopoulos C., Athanassiou P., Gogas J., Proukakis C. Thyroid function in postmenopausal women with breast cancer on tamoxifen. Eur. J. Gynaecol. Oncol. 9:1998;150-154.
23. Laws S.C., Ferrell J.M., Stoker T.E., Schmid J., Cooper R.L. The effects of atrazine on female Wistar rats. an evaluation of the protocol for assessing pubertal development and thyroid function Toxicol. Sci. 58:2000;366-376.
24. Mitsumori K., Onodera H., Takahashi M., Shimo T., Yasuhara K., Kitaura K., Takahashi M., Hayashi Y. Effect of thyroid stimulating hormone on the development and progression of rat thyroid follicular cell tumors. Cancer Lett. 92:1995;193-202.
25. Son H.-Y., Nishikawa A., Ikeda T., Nakamura H., Miyauchi M., Imazawa T., Furukawa F., Hirose M. Lack of modifying effects of environmental estrogenic compounds on the development of thyroid proliferative lesions in male rats pretreated with N-bis(2-hydroxypropyl)nitrosamine (DHPN). Jpn. J. Cancer Res. 91:2000;899-905.
26. Stevens J.T., Breckenridge C.B., Wetzel L. A risk characterization for atrazine. oncogenicity profile J. Toxicol. Environ. Health. 56:1999;69-109.
27. Stoker T.E., Guidici D.L., Laws S.C., Cooper R.L. The effects of atrazine metabolites on puberty and thyroid function in the male Wistar rat. Toxicol. Sci. 67:2002;198-206.
28. Tennant M.K., Hill D.S., Eldridge J.C., Wetzel L.T., Breckenridge C.B., Stevens J.T. Possible antiestrogenic properties of chloro-S-triazines in rat uterus. J. Toxicol. Environ. Health. 43:1994;183-196.
29. Waritz R.S., Steinberg M., Kinoshita F.K., Kelly C.M., Richter W.R. Thyroid function and thyroid tumors in toxaphene-treated rats. Regul. Toxicol. Pharmacol. 24:1996;184-192.
30. Wetzel L.T., Luempert L.G. 3rd, Breckenridge C.B., Tisdel M.O., Stevens J.T., Thakur A.K., Extrom P.J., Eldridge J.C. Chronic effects of atrazine on estrus and mammary tumor formation in female Sprague-Dawley and Fischer 344 rats. J. Toxicol. Environ. Health. 43:1994;169-182.
31. Wilson A.G., Thake D.C., Heydens W.E., Brewster D.W., Hotz K.J. Mode of action of thyroid tumor formation in the male Long-Evans rat administered high doses of alachlor. Fundam. Appl. Toxicol. 33:1996;16-23.
32. Yang K., Pearson C.E., Samaan N.A. Estrogen receptor and hormone responsiveness of medullary thyroid carcinoma cells in continuous culture. Cancer Res. 48:1988;2760-2763.
33. Zhou L.X., Dehal S.S., Kupfer D., Morrell S., McKenzie B.A., Eccleston E.D. Jr., Holtzman J.L. Cytochrome P450 catalyzed covalent binding of methoxychlor to rat hepatic, microsomal iodothyronine 5′-monodeiodinase, type I: does exposure to methoxychlor disrupt thyroid hormone metabolism? Arch. Biochem. Biophys. 322:1995;390-394.
34. Zidan J., Rubenstein W. Effect of adjuvant tamoxifen therapy on thyroid function in postmenopausal women with breast cancer. Oncology. 56:1999;43-45.